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352 The Journal of Thoracic and CardioObjective: We sought to evaluate the effects of pexelizumab, a C5 complement
inhibitor, on death and myocardial infarction in patients undergoing combined aortic
valve replacement and coronary artery bypass grafting surgery.
Methods: The Pexelizumab for Reduction in Myocardial Infarction and Mortality in
Coronary Artery Bypass Graft surgery trial, a phase III prospective, randomized,
double-blind, placebo-controlled study, enrolled 3099 patients at 205 centers. The
primary end point was the composite of death, myocardial infarction, or both at
postoperative day 30 in patients undergoing coronary artery bypass grafting without
valve surgery. Postoperative myocardial infarction was defined as a creatine kinase MB
fraction value of 100 ng/mL or greater, Q-wave myocardial infarction with a creatine
kinase MB fraction value of 70 ng/mL or greater, or new Q-wave evidence of myo-
cardial infarction by postoperative day 30. Because patients undergoing coronary artery
bypass grafting with a valve procedure were not included in the primary population,
separate analysis of death and myocardial infarction was conducted in 218 patients
undergoing combined aortic valve replacement and coronary artery bypass grafting
surgery.
Results: Of the 353 patients randomized to any valve procedure, 106 (61%) underwent
combined aortic valve replacement and coronary artery bypass grafting in the pexeli-
zumab treatment group compared with 112 (63%) patients in the placebo group.
Coronary artery bypass grafting was performed with 1 or more internal thoracic artery
grafts in 139 (64%) patients and with 1 or more saphenous vein grafts in 179 (82%)
patients. There were 4 (3.8%) deaths in the pexelizumab group versus 11 (9.9%) in the
placebo group by postoperative day 30 and 6 (5.7%) deaths in the active group versus
16 (14.4%) in the placebo group by postoperative day 180 (P .107 and P .043,
respectively, Fisher exact test). The incidence of myocardial infarction 30 days after
surgical intervention was identical in the 2 groups, but the study was not designed to
detect differences in this cohort of patients.
Conclusions: Inhibition of complement activation by pexelizumab resulted in a de-
creased mortality at 180 days among 218 patients who underwent combined aortic valve
replacement and coronary artery bypass grafting surgery. Additional studies are war-
ranted to confirm this decrease in mortality with pexelizumab in combined aortic valve
replacement and coronary artery bypass grafting procedures.
Pexelizumab is a novel recombinant, single-chain, and humanized anti-C5monoclonal antibody fragment recently shown to decrease myocardial in-farction (MI) and mortality rates after coronary artery bypass grafting
(CABG).1 Experimental evidence suggests that inhibitio
vascular Surgery ● February 2006n of C5 conversion to C5a
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cardiopulmonary bypass (CPB) and reperfusion of ischemic
myocardium.2,3 Human studies have also shown a beneficial
effect of C5 inhibition on inflammation markers, MI rate
determined on the basis of creatine kinase MB fraction
(CK-MB), and postoperative death in that setting.4
The Pexelizumab for Reduction in Infarction and Mor-
tality in Coronary Artery Bypass Graft surgery (PRIMO-
CABG) trial enrolled 3099 patients, of whom 218 under-
went combined aortic valve replacement (AVR) and
CABG5 between January 2002 and February 2003. Patients
undergoing combined valve and coronary artery surgery
represent a complex subgroup of patients at a much higher
risk for morbidity and mortality after surgical intervention
compared with patients undergoing isolated CABG. The
present study analyzes results of a subgroup of patients of
the PRIMO-CABG trial. Patients who underwent combined
AVR and CABG and who were recruited in the PRIMO-
CABG trial formed the present group of interest for the
study.
Patients and Methods
Patient Population
The study population, design, and main findings of the PRIMO-
CABG trial have already been published.5 In summary, the trial
was conducted at 205 sites in North America and Western Europe.
Eligible patients included those scheduled for CABG with or
without concurrent valve surgery. The study included patients with
one or more of the following baseline risk factors: urgent inter-
vention, diabetes mellitus, female sex, prior CABG procedure,
history of a neurologic event, history of congestive heart failure
(New York Heart Association class III or IV), or history of 2 or
more MIs (excluding patients who have had an MI within 48 hours
of CABG) or an MI that occurred 48 hours or more but 4 or fewer
weeks before CABG. Exclusion criteria included planned aortic
dissection repair, required aortic root reconstruction, or both; re-
quired salvage intervention; current cardiogenic shock; acute left
ventricular, septal, or acute papillary muscle rupture; uncontrolled
diabetes; history of renal failure and a serum creatinine value of
greater than 3.0 mg/dL; history of chronic hepatic failure, hepatic
cirrhosis, or both; and a history of malignancy, known or suspected
hereditary complement deficiency, and any active infection. The
institutional review boards or equivalent approved the protocol at
each site, and all patients provided written consent.
Study Protocol
Patients were randomized in a double-blind fashion to receive
either intravenous pexelizumab (2.0 mg/kg bolus followed by 0.05
mg · kg1 · h1 infusion for 24 hours) or placebo (placebo bolus
followed by 24-hour infusion). Stratification occurred within each
site and was based on whether valve surgery was planned, the type
of valve surgery performed (mitral or other valve), and whether
primary or repeat CABG was scheduled. Pexelizumab or placebo
bolus was administered as soon as possible after anesthesia induc-
tion but no later than 10 minutes before CPB. Patients were
followed for in-hospital adverse events and clinical end points. In
The Journal of Thoraciaddition, patients were seen 14, 30, and 90 days after CABG
surgery for adverse events and clinical outcomes and were con-
tacted by telephone at 6 months to determine survival status.
Study End Points
For the present study focusing on patients undergoing AVR and
CABG, death, MI, and complications were analyzed 30 and 90
days after surgical intervention, and survival status was also stud-
ied at 180 days. Death was defined as all-cause mortality. MI
included both Q-wave and non-Q-wave MIs. A clinical events
committee consisting of 3 expert cardiologists blinded to patient
treatment assignment adjudicated all MIs. Through postoperative
day (POD) 4, the diagnosis of a Q-wave MI required a new
Q-wave persisting through POD 30 or associated with a peak
CK-MB value of 70 ng/mL or greater; non-Q-wave MI required a
peak CK-MB value of 100 ng/mL or greater within 96 hours
postoperatively and without a new Q-wave. CK-MB measure-
ments were collected at 4, 8, 12, 16, 24, 72, and 96 hours postop-
eratively and analyzed at a central core laboratory. Troponin I
measurements were collected immediately before surgical inter-
vention and on days 1, 2, and 4 after surgical intervention. Elec-
trocardiograms were recorded at patient enrollment, as well as 48
and 96 hours and 14, 30, 90, and 180 days postoperatively. All
electrocardiograms for the primary end point and prespecified
secondary analyses were read at a central core laboratory. The
pharmacodynamic effect of pexelizumab (inhibition of serum
complement activity) was determined by using a standard total
serum complement assay, as previously described.6
Statistical Analyses
The present report focused solely on patients recruited in the trial
who underwent combined AVR and CABG. Patients who under-
went isolated CABG and those who underwent CABG with an-
other valve procedure at surgical intervention were excluded. The
Wilcoxon rank sum test was performed on continuous data, and the
Fisher exact test was used in comparing incidence rates. Survival
analysis included Kaplan-Meier curve estimation.
Results
Patient Characteristics and Operative Data
Of the 218 patients undergoing AVR and CABG, 106 were
randomized to receive intravenous administration of pexeli-
Abbreviations and Acronyms
AVR  aortic valve replacement
CABG  coronary artery bypass grafting
CK-MB  creatine kinase MB fraction
CPB  cardiopulmonary bypass
MI myocardial infarction
POD  postoperative day
PRIMO-CABG Pexelizumab for Reduction in
Infarction and Mortality in Coronary
Artery Bypass Graft surgeryzumab during the first 24 hours after surgical intervention
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who were allocated to the placebo group. Patients in both
groups were mostly male and averaged 73 years old. Aortic
stenosis was the main indication for AVR in the 2 groups of
patients. Fourteen percent and 13% of the patients, respec-
tively, underwent reoperative CABG (Table 1).
The average crossclamp and CPB times were similar in the
2 groups. The use of internal thoracic artery and saphenous
vein grafts was also similar between the 2 groups (Table 2).
Adverse Events and Pharmacodynamics
The most common adverse events reported were atrial fi-
brillation and pleural effusion, with a similar incidence
TABLE 1. Patient characteristics
Pexelizumab (n  1
Age (y) 73 8
Female sex 39 (37%)
NYHA class III and IV 43 (41%)
Aortic valve insufficiency 8 (7.5%)
Reoperative CABG 15 (14%)
Prior myocardial infarction 20 (18.9%)
NYHA, New York Heart Association; CABG, coronary artery bypass graft
TABLE 2. Operative data
Pexelizum
Crossclamp time (min) 10
CPB time (min) 14
ITA grafts 66
SV grafts 92
No. of coronary artery grafts per patient
CPB, Cardiopulmonary bypass; ITA, internal thoracic artery; SV, saphenou
TABLE 3. Adverse events and infection logs through 90 da
Pexe
Atrial fibrillation
Pleural effusion
Acute renal failure
Cardiac tamponade
Complete AV block
Septicemia
Endocarditis
Pneumonia
Sternal wound infection
Superficial
Deep
Wound infection at the leg vein harvesting site
Urinary tract infection
Stroke
AV, Atrial ventricular.reported between groups (Table 3). Of interest, septicemia
354 The Journal of Thoracic and Cardiovascular Surgery ● Febrand pneumonia were more frequent in the placebo group
compared with in the pexelizumab group. Endocarditis and
sternal wound infection rates were similar in the 2 groups.
Stroke rates were not statistically different between the 2
groups. Pexelizumab bolus and 24-hour infusion resulted in
an inhibition of total serum complement hemolytic activity,
which recovered to baseline levels 72 hours after surgical
intervention (Figure 1).
Clinical Outcomes
Four patients (4/106 [3.8%]) in the pexelizumab group and
11 (11/112 [9.9%]) in the placebo group died within the first
30 days after surgical intervention (P .107), suggesting a
Placebo (n  112) P value
73 9 .635
43 (38%) .889
53 (48%) .341
12 (10.7%) .486
15 (13%) 1.000
27 (24.1%) .411
ry.
 106) Placebo (n  112) P value
3 107  3 .979
5 147  4 .870
) 73 (65%) .675
) 87 (78%) .111
2.2 .336
n.
ab (n  104) Placebo (n  110) P value
26.9%) 30 (27.3%) 1.000
25%) 26 (23.6%) .874
3.8%) 4 (3.6%) 1.000
2.9%) 2 (1.8%) .676
2.9%) 1 (0.9%) .358
2%) 11 (10.2%) .019
1 (0.9%) 1.000
3.9%) 13 (11.9%) .042
2%) 4 (3.7%) .684
2%) 1 (0.9%) .61
9.8%) 5 (4.6%) .18
5.9%) 17 (15.7%) .001
1.9%) 9 (8.2%) .0606)ab (n
6
6
(62%
(87%
2.4ys
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[21%]) patients and in the placebo group 23 (23/112 [21%])
patients met the previously defined criteria for postoperative
MI within the first 30 days after surgical intervention (P 
1.000). Q-wave MI was documented in 7 (7/106 [6.6%])
and 3 (3/112 [2.7%]) patients, respectively (P .205). Non-
Q-wave MI was documented in 15 (15/106 [14.2%]) and 20
(20/112 [17.9%]) patients, respectively (P .64). The com-
posite of death, MI, or both occurred in 23 patients (23/106
[22%]) in the pexelizumab group and in 31 patients (31/111
[28%]) in the placebo group (P .44)
At 90-day follow-up, 5 patients (5/106 [4.7%]) in the
pexelizumab group and 15 patients (15/112 [13.5%]) in the
control group had died (P .034). Pexelizumab reduced the
risk of death by 65%. At 180-day follow-up, mortality rates
averaged 5.7% (6/106) and 14.4% (16/112), respectively (P
.043), a risk reduction of 60% among patients treated with
pexelizumab (Figure 2).
The causes of death at 180-day follow-up among
pexelizumab-treated patients were MI in 2 patients, renal
failure in 1 patient, disseminated intravascular coagulation
in 1 patient, multiorgan failure in 1 patient, and an unspec-
ified cause in a last patient. Among the latter patients, one
death from MI occurred at POD 31, and another occurred at
POD 88 from renal failure. In the placebo group the causes
of death at 180-day follow-up were cerebral complication
(stroke and bleeding) in 3 patients, sepsis in 3 patients,
respiratory failure in 2 patients, congestive heart failure in 2
patients, renal failure in 1 patient, cardiogenic shock in 1
patient, multiorgan failure in 1 patient, pulmonary artery
trauma at surgical intervention in 1 patient, sudden cardiac
death in 1 patient, and a noncardiac cause in a last patient.
Among the latter patients, 1 patient died from cerebral
Figure 1. Serum complement activity measure with a standard
complement hemolysis assay. *P <.01 between the 2 groups at 4
and 24 hours, Wilcoxon rank sum test.complication at POD 32 after surgical intervention, 1 pa-
The Journal of Thoracitient died from sepsis at POD 46, 1 patient died from renal
failure at POD 71, 1 patient died from cardiac arrest at POD
83, and 1 patient died from a non–cardiac-related cause 158
days after surgical intervention.
Discussion
The present study showed that inhibition of complement
activation by pexelizumab resulted in a decreased mortality
at 90 and 180 days among patients who underwent com-
bined AVR and CABG surgery. An important mechanism
of cardiac injury during cardiac surgery is the excessive
activation of the complement cascade related to ischemia
and reperfusion, contact activation, and general systemic
inflammation from CPB. Pexelizumab, a humanized anti-C5
complement antibody fragment, prevents cleavage of C5,
thus mitigating the effects of the terminal complement com-
ponents C5a and C5b-9 on vascular permeability, chemoat-
traction, and cellular activation, with subsequent cytokine
release that might result in myocardial cell damage, sys-
temic inflammation, and apoptosis.3
Fitch and colleagues4 first reported that sC5b-9, leuko-
cyte activation through CD11b expression, myocardial in-
jury determined on the basis of CK-MB measurements, and
cognitive deficits determined with preoperative and postop-
erative tests were significantly reduced in patients who
received pexelizumab. These authors have established that
effective inhibition of human C5 has a profound anti-
inflammatory effect on patients undergoing CABG with
CPB.
In a phase II prospective, multicenter, randomized,
placebo-controlled trial, Shernan and associates1 suggested
that MI and mortality could be decreased with pexelizumab
in patients undergoing CABG. The PRIMO-CABG trial
then enrolled 3099 patients: 2732 (88%) underwent isolated
Figure 2. Actuarial survival.CABG, and 353 (11%) underwent combined valve surgery
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CABG. The primary end point of combined death or MI 30
days after surgical intervention was reduced by 18% in
patients undergoing isolated CABG treated with pexeli-
zumab. Pexelizumab was associated with a significant de-
crease in death or MI rate 180 days after surgical interven-
tion. Although the study was not powered for detecting
differences in mortality, death alone was not affected by
pexelizumab in patients undergoing isolated CABG.
Compared with patients undergoing isolated CABG, our
subgroup of patients undergoing AVR plus CABG was
older, had a greater proportion of repeat CABG, and was
less likely to have experienced a preoperative MI. Of inter-
est, mortality at 90 and 180 days after surgical intervention
was decreased in patients treated with pexelizumab in our
substudy patients who underwent combined AVR and
CABG.
Several studies have reported difficulties in obtaining
optimal myocardial protection during AVR because of as-
sociated left ventricular hypertrophy.7 Shernan and associ-
ates1 show that patients undergoing AVR plus CABG re-
lease more CK-MB after surgical intervention than patients
undergoing isolated CABG (median CK-MB peak release
of 50 ng/mL vs 30 ng/mL, respectively). The greater release
of CK-MB after AVR explains the high rate of MI reported
in these patients compared with that seen in patients under-
going isolated CABG. The high rate of MI in the 2 groups
(45/218 [21%]), although mostly non-Q-wave, is related to
the definition of postoperative MI based on the experience
gained with the study of patients undergoing isolated
CABG. Although Klatte and coworkers8 showed a relation
between the release of CK-MB after isolated CABG and
6-month mortality in studying patients in the Guardian trial,
whether this link is applicable to patients undergoing AVR
remains to be proved.
The important limitation of the present study remains
related to the subanalysis of the main trial. Therefore the
difference in mortality in this report might not be clinically
356 The Journal of Thoracic and Cardiovascular Surgery ● Febrimportant, and a prospective randomized trial is required
before cardiac surgeons adopt this therapy for this indica-
tion. The present post-hoc analysis raises the hypothesis that
pexelizumab decreases early and 6-month mortality after
combined AVR and CABG surgery. The effect of pexeli-
zumab could be related to a decrease in the extent of
myocardial ischemic injury and inhibition of inflammation
cascades, leading to end-organ damage with the use of CPB
in patients undergoing combined AVR and CABG. Further
studies are needed to confirm this effect of the anti-C5
antibody pexelizumab.
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